# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-19T11:00:10.638703
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 15043 in / 4782 out
**Response SHA256:** e24dce39a76bcddf

---

## Referee Report: “Click to Prescribe: Do Electronic Prescribing Mandates Reduce Opioid Mortality?”

### Summary
The paper studies whether state mandates requiring electronic prescribing for controlled substances (EPCS) reduce opioid overdose mortality. It uses state-by-year variation in mandate effective dates (33 treated states, 18 never-treated) and estimates effects on (i) prescription opioid deaths (ICD-10 T40.2) and (ii) a “built-in” placebo outcome—synthetic opioid deaths (T40.4, largely illicit fentanyl). The main design is a modern staggered DiD using Callaway & Sant’Anna (CS), with robustness to Sun & Abraham and TWFE comparisons. The headline result is an ~18% reduction in prescription-opioid mortality in logs (ATT = −0.199, SE = 0.085), while level estimates are negative but imprecise; placebo effects are null.

The topic is important and under-studied relative to PDMPs and prescribing limits, and the placebo outcome is a real strength. The draft is promising, but several issues—especially around outcome construction (rolling totals), missing/suppressed cells, inference presentation consistency, and the interpretation of the log specification with a hard floor—need substantial tightening for a top general-interest journal.

---

## 1. FORMAT CHECK

### Length
- **Approximate length**: The main text appears to be roughly **20–25 pages** in 12pt, 1.5 spacing, excluding references/appendix (hard to be exact from LaTeX alone). It is **close to the 25-page threshold** but may come in slightly under once rendered depending on figures/tables. If aiming for AER/QJE/JPE/ReStud/Ecta, ensure the **main paper is clearly ≥25 pages** excluding references and appendix, with full empirical details (especially around data suppression and outcome construction).

### References
- The bibliography (not shown) is invoked, and the text cites major DiD methodology papers and key opioid-policy papers.
- **Likely gaps** remain (see Section 4 below), particularly on (i) event-study inference pitfalls, (ii) staggered DiD implementation details and diagnostics, (iii) small-cluster inference, and (iv) measurement issues in overdose coding and provisional data.

### Prose
- Major sections (Intro, Institutional Background, Data, Strategy, Results, Discussion) are written in **paragraph form**, not bullets. Good.

### Section depth
- Most major sections have **3+ substantive paragraphs**, except:
  - **Conceptual Framework** is relatively short and partly structured as enumerated “channels/predictions.” This is fine stylistically, but for a top outlet it would benefit from **more fully developed paragraphs** and clearer mapping from mechanisms → empirical implications (especially heterogeneity predictions, timing, and interactions with PDMPs).

### Figures
- Figures are included via `\includegraphics`. Since this is LaTeX source, I **do not flag figure visibility**, but in the final PDF ensure:
  - Axes labeled, units clear (deaths per 100k; log points), event-time definitions explicit, and confidence bands legible.
  - Event-study figures should show **number of states/cohorts contributing at each event time** (“stacked” support).

### Tables
- Tables contain **real numbers**, standard errors, and CIs. No placeholders. Good.

---

## 2. STATISTICAL METHODOLOGY (CRITICAL)

Overall, the paper is *much closer to the bar* than many policy DiD papers because it uses CS-DiD and reports clustered SEs and (some) CIs. But there are several issues that should be addressed explicitly and consistently.

### (a) Standard Errors
- **PASS** in the main tables: coefficients generally have **SEs in parentheses**.
- However:
  - **Panel D (log specification)** in Table 2 does not report a 95% CI there (though Table 3 does). For readability and compliance with your own standard, add **95% CIs for the log ATT** wherever it appears.

### (b) Significance Testing
- **PASS**: p-values and star notation are provided, and placebo tests are conceptually used.
- But: the paper should be careful not to over-weight “significant in logs” vs “not significant in levels” as a purely statistical narrative. This is partly addressed, but the **choice of estimand** needs stronger grounding.

### (c) Confidence Intervals
- **Partially PASS**:
  - Panel A includes 95% CIs.
  - Robustness table includes 95% CIs.
  - But not consistently reported across all panels/specifications (e.g., TWFE/Sun-Abraham panels lack CIs; log panel in Table 2 lacks CI).
- Suggestion: For the primary outcome and placebo, **standardize reporting**: coefficient, SE, **95% CI**, N, and clusters for *every* estimator you show.

### (d) Sample Sizes
- **Mostly PASS**: N is reported (Observations = 337) and number of states (48).
- But there is an important conceptual issue: the “panel” is 2015–2023 (459 potential state-years), yet regressions use **N = 337** due to suppression and the requirement of non-missing across outcomes.
  - You should report, **for each outcome**, the effective N and number of states, because suppression differs by drug class and is likely outcome-dependent.
  - If you force a common sample across outcomes (as stated), defend that choice and show that results are not driven by that restriction (e.g., estimate each outcome on its **maximal available sample** and compare).

### (e) DiD with Staggered Adoption
- **PASS on estimator choice**: You use **Callaway & Sant’Anna** and discuss TWFE problems, plus Sun-Abraham robustness.
- However, I see three *methodological vulnerabilities* that need more work:
  1. **Outcome is “12-month-ending totals reported for December”** (rolling annual totals). This induces **mechanical serial correlation and treatment contamination across adjacent years**. A mandate effective mid-year will affect the December 12-month total partly in the adoption year and partly in the next year. This is not fatal, but it must be modeled carefully (see suggestions below).
  2. **Clustering and inference with 48 clusters**: state-clustered SEs are standard, but for top journals you should also show robustness to **wild cluster bootstrap** p-values / randomization inference / placebo adoption timing, especially given staggered adoption and moderate cluster counts.
  3. **Support by event time**: because adoption is highly clustered in 2020–2021, later event-time coefficients are identified off a small number of cohorts. You mention this qualitatively; you should show **event-time sample support**.

### (f) RDD
- Not applicable.

**Bottom line on methodology:** Not a “fatal fail,” but the rolling-total outcome and suppression handling are sufficiently important that I would consider them **core identification/inference risks** until addressed transparently.

---

## 3. IDENTIFICATION STRATEGY

### Credibility
Strengths:
- **Policy variation**: staggered mandates with a plausible federal timing anchor (SUPPORT Act).
- **Modern staggered DiD**: avoids known TWFE bias.
- **Built-in placebo**: synthetic opioid deaths (T40.4) is an excellent falsification target in principle.

Concerns / what needs strengthening:
1. **Rolling 12-month totals** (December “12-month-ending”):
   - These are not standard annual counts; they are **rolling sums**, making the timing of treatment effects ambiguous and potentially smearing pre/post patterns.
   - This can **attenuate pre-trend tests** (pre-period already includes some post months if coding is not aligned) and complicate anticipation assumptions.
   - You should either (i) switch to true calendar-year death counts (if available), or (ii) explicitly model the rolling window and show robustness.

2. **Non-random missingness / suppression**:
   - Dropping suppressed cells (counts < 10) will disproportionately drop small states and low-mortality state-years. If treatment affects whether a cell is suppressed (by lowering deaths below 10), you may induce **selection on the outcome**.
   - This is potentially serious. You discuss it, but discussion is not enough; you need empirical strategies:
     - Use **bounds / imputation / partial identification** approaches.
     - Or re-aggregate to outcomes less prone to suppression (e.g., counts rather than rates? multi-year pooling?).

3. **Pandemic confounding**:
   - Many adoptions occur in 2020–2021. COVID is not just a common shock; it may generate **state-specific differential shocks** correlated with adoption (e.g., states with certain health system capacity or political preferences both adopted EPCS and experienced different overdose dynamics).
   - The placebo outcome helps, but polysubstance overlap means the placebo is not “clean.” Also, the pandemic could differentially affect prescription vs fentanyl channels (telemedicine prescribing changes, fentanyl supply shocks, etc.).
   - You should add additional falsification outcomes (see Section 6).

4. **Treatment definition and compliance**
   - Mandates differ: exemptions (hospitals, veterinarians, temporary waivers, rural areas), schedules covered, enforcement dates vs effective dates.
   - A mandate is not the same as actual EPCS utilization. Without utilization data, you are estimating an **ITT** of mandate enactment.
   - For publication, you need a clearer **taxonomy of mandate strength** and at least some validation that mandates increased EPCS usage sharply (first stage), perhaps using Surescripts or state pharmacy board stats if accessible.

### Placebos, robustness, and limitations
- Event-study pre-trends are presented (figure), but you should also:
  - Report a **formal pre-trends test** (e.g., joint test of leads) and/or Rambachan-Roth honest DiD results in the main text (not only mentioned).
  - Conduct **placebo adoption timing** (randomly assign adoption years preserving cohort sizes) to show your estimated ATT is unusual under the null.

### Do conclusions follow from evidence?
- The paper is generally careful, but it sometimes reads as if the causal claim hinges on the log result being significant. For a top journal, tighten:
  - Clarify that the preferred estimand is proportional (and why), and treat level results as a secondary estimand rather than “imprecise but supportive.”

---

## 4. LITERATURE (Missing references + BibTeX)

You cite core staggered DiD papers (Callaway-Sant’Anna; Sun-Abraham; Goodman-Bacon; de Chaisemartin & D’Haultfoeuille). That’s good. For a top journal, I recommend adding at least the following categories:

### (i) Event-study and DiD inference / pre-trends pitfalls
- **Roth (2022)** on pre-trends power and interpretation.
- **Borusyak, Jaravel & Spiess (2021)** on imputation DiD (useful robustness).
- **Roth, Sant’Anna, Bilinski & Poe (2023)** on DiD event-study practices / sensitivity.
- **Young (2019)** (or related) on “credibility revolution” inference fragility (optional, but can help framing).

BibTeX:
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year    = {2022},
  volume  = {4},
  number  = {3},
  pages   = {305--322}
}

@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}

@article{RothSantAnnaBilinskiPoe2023,
  author  = {Roth, Jonathan and Sant'Anna, Pedro H. C. and Bilinski, Alyssa and Poe, John},
  title   = {What's Trending in Difference-in-Differences? A Synthesis of the Recent Econometrics Literature},
  journal = {Journal of Econometrics},
  year    = {2023},
  volume  = {235},
  number  = {2},
  pages   = {2218--2244}
}
```

*(If you prefer only peer-reviewed, keep Roth 2022 and Roth et al. 2023; BJ&S is widely used but still a working paper depending on version.)*

### (ii) Small-cluster / DiD inference
Given 48 clusters and heavy policy clustering in time, cite inference guidance:
```bibtex
@article{CameronGelbachMiller2008,
  author  = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title   = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year    = {2008},
  volume  = {90},
  number  = {3},
  pages   = {414--427}
}

@article{MacKinnonWebb2017,
  author  = {MacKinnon, James G. and Webb, Matthew D.},
  title   = {Wild Bootstrap Inference for Wildly Different Cluster Sizes},
  journal = {Journal of Applied Econometrics},
  year    = {2017},
  volume  = {32},
  number  = {2},
  pages   = {233--254}
}
```

### (iii) Opioid mortality measurement / death certificate limitations
To support claims about coding variation and polysubstance classification, consider adding epidemiology/public health measurement references (even in econ journals, this is increasingly standard). For example:
```bibtex
@article{Ruhm2018,
  author  = {Ruhm, Christopher J.},
  title   = {Corrected U.S. Opioid-Involved Drug Poisoning Deaths and Mortality Rates, 1999--2015},
  journal = {Addiction},
  year    = {2018},
  volume  = {113},
  number  = {7},
  pages   = {1339--1344}
}
```

### (iv) E-prescribing / EPCS-related policy and adoption literature
You cite Yang et al. (2020). I suspect there is additional health policy literature on EPCS and diversion, even if not causal. You should search and cite it; a top journal referee will ask “is it really the first causal evidence?” You can keep the claim, but back it with a more systematic search.

---

## 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- **PASS**: major sections are paragraph-based.
- The conceptual framework uses italicized “Channel 1/2/3.” That is acceptable, but for readability consider converting each channel into a short paragraph with topic sentence + mechanism + testable implication, rather than list-like formatting.

### (b) Narrative flow
- Strong: clear motivation, institutional detail, and why staggered adoption helps.
- The most important narrative gap: the paper should **more explicitly foreground the key empirical challenge**: EPCS mandates coincide with (i) the fentanyl wave and (ii) COVID-era upheavals and (iii) many other opioid policies. Your placebo helps, but the introduction should be more explicit about why placebo + staggered DiD + robustness is enough.

### (c) Sentence quality
- Generally crisp and professional. Some claims are a bit assertive relative to evidence (e.g., “political economy … plausibly orthogonal”): tone these down or support with data (e.g., correlations of adoption timing with pre-trends or with baseline mortality).

### (d) Accessibility
- Very good for non-specialists: explains EPCS vs PDMP well.
- Improve by contextualizing magnitudes: translate −0.199 log points into **lives saved** nationally per year using baseline rates and population, with uncertainty intervals.

### (e) Tables
- Tables are mostly clear.
- Add consistent notes on:
  - Whether outcomes are **rates or counts** in each column.
  - Whether the CS-DiD uses outcome regression covariates and what they are (currently unclear—what enters the propensity score/outcome model?).
  - How missingness is handled in each estimator.

---

## 6. CONSTRUCTIVE SUGGESTIONS (How to make it stronger and more publishable)

### A. Fix / re-think the outcome construction (highest priority)
Right now the “annual” outcome is December’s **12-month-ending rolling total**. This can distort timing.

Concrete fixes:
1. **Prefer true calendar-year counts** (NVSS final or restricted-use) if feasible. If not:
2. Use **monthly data** (VSRR has state-month) and estimate on a monthly panel with appropriate seasonality controls and event time in months. That would:
   - Increase T (power),
   - Better align treatment timing,
   - Allow cleaner anticipation and dynamic effects,
   - Reduce the “rolling-window mechanical smoothing” problem.
3. If you must keep 12-month-ending totals, add an explicit section explaining:
   - Why December’s rolling total is a good proxy for calendar-year,
   - How treatment in year g enters outcome in year g (partial exposure) and g+1 (full exposure),
   - How you code event time under rolling totals.

### B. Address suppression/missingness as an identification threat (also highest priority)
Do more than acknowledge it.

Options (you can do several):
1. **Show robustness to alternative aggregation**:
   - Combine T40.2 with another prescription-related category, or use “all opioids excluding T40.4” if definable, to reduce suppression.
2. **Model suppressed cells**:
   - Treat suppressed counts as interval-censored (0–9) and implement a bounds approach on rates and on log(1+count).
3. **Don’t require a common sample across outcomes**:
   - Estimate each outcome on its maximum sample; then show that the placebo result remains null and the treatment effect remains negative.
4. **Balance checks on missingness**:
   - Regress an indicator for being observed (not suppressed) on treatment/event time to test whether mandates change observability.

### C. Strengthen inference beyond clustered SEs
Add at least one of:
- **Wild cluster bootstrap** p-values for the main ATT.
- **Randomization inference** / permutation tests using placebo adoption years (especially valuable given adoption clustering).
- Report **HonestDiD** sensitivity results (Rambachan-Roth) in a main-text table/figure: “How large would deviations from parallel trends need to be to explain away −0.199?”

### D. Mechanisms / heterogeneity (to elevate contribution)
Right now mechanisms are discussed but not tested.

Feasible extensions:
1. **Interaction with PDMP must-access** (Prediction 2):
   - Estimate CS-DiD separately for PDMP-strong vs PDMP-weak states at baseline, or implement an interaction/event study approach (careful with power).
2. **Baseline diversion risk** proxies:
   - Pre-period rates of prescription opioid deaths, opioid prescribing rates (CDC prescribing data), or “pill mill” indicators.
   - If EPCS works via fraud/diversion, effects should be larger where diversion was more plausible.
3. **Other placebo outcomes**:
   - Non-opioid drug deaths plausibly unrelated to prescribing format (e.g., psychostimulants T43.6) as additional falsification.
4. **First stage validation**:
   - If you can obtain EPCS utilization (% controlled substance scripts sent electronically) from Surescripts, state boards, or CMS, show that mandates produce a sharp increase.

### E. Tighten the interpretation of the log specification
Using `log(max(Y,1))` is pragmatic, but it is not innocuous.

Suggestions:
- Consider **Poisson PML** (or negative binomial) with population offset at the state-year level; PPML naturally handles zeros and often behaves well for skewed count/rate outcomes.
- Or use **log(1+Y)** rather than hard floor at 1 (if Y is a rate, flooring at 1 is large relative to many states).
- At minimum, show robustness to:
  - log(1+rate),
  - inverse hyperbolic sine,
  - PPML on counts with offset.

### F. Clarify what CS “doubly robust” model includes
The paper says it uses the CS doubly robust estimator, but does not clearly state:
- What covariates enter the propensity score / outcome regression (beyond fixed effects logic).
- Whether you include state-specific trends, region-by-year shocks, etc.

For transparency, include:
- A short “implementation details” subsection: covariates, weighting, trimming, overlap checks.

---

## 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with genuine gap: EPCS mandates are widespread and under-evaluated.
- Uses **appropriate modern staggered DiD** and reports multiple estimators.
- The **drug-class placebo** is a compelling design element and well-motivated.
- Institutional background is clear and helps readers understand the mechanism.

### Critical weaknesses (fixable but substantial)
1. **Outcome construction (rolling 12-month totals)** creates timing ambiguity and potential bias/attenuation.
2. **Suppression-driven missingness** may induce selection and needs formal handling/robustness.
3. Inference should be strengthened with **alternative inference procedures** and clearer event-time support.
4. The “significant-in-logs” result relies on a log transform with a **hard floor**, which needs more robustness or a better modeling strategy (PPML / asinh / log1p).

### Specific improvement priorities
1. Re-estimate on monthly data or calendar-year counts; otherwise, fully justify and model the rolling total.
2. Add missingness/suppression diagnostics and bounds/robustness.
3. Add wild cluster bootstrap / randomization inference + honest DiD sensitivity in main text.
4. Expand mechanism/heterogeneity tests and add additional placebo outcomes.

---

DECISION: MAJOR REVISION